The Chennai based Medopharm Pvt Ltd announced launch of an antibiotic, cledomox, a combination of amoxicillin and clavulanic acid for treating infections. The product is manufactured at the newly launched manufacturing plant for beta-lactum and anti-biotic products.

Cledomox is the first of the beta-lactum products to be produced at the new facility, which has UK MHRA and US FDA standards. The Rs 25 crore facility will manufacture more products, company officials said in a press conference.

Cledomox tackles a range of infections including sinusitis, bronchitis, urinary tract infections, skin and soft tissue infections and the product would cater to both domestic and export markets, said Gambhir Chordia, director of Marketing, Medopharm.

Medopharm has manufacturing facilities near Bangalore and Hyderabad and recorded around Rs 150 crore sales in the fiscal 2005-06. Exports accounted for almost three-fourth of the sales in the last financial year. The company expects to increase its sales to Rs 200 crore in the current fiscal, by leveraging the potential of upcoming products in the pipeline, which add to the existing products product portfolio, informed the officials.